Skip to main content
1491 results

CERTAINTY by Certara 2024

Transcript: The Certara community and interdisciplinary industry experts and scientists from model and form drug development bio simulation, clinical pharmacology, regulatory science, and software development come together for Certainty. Certara’s first annual client summit. This coming May fourteenth through sixteenth in Philadelphia at Convene. We will unite to share future visions, strategies, industry trends, and … Continued

https://www.certara.com/video/certainty-by-certara-2024/

Certara Reports Fourth Quarter 2023 Financial Results

Provides Full Year 2024 Financial Guidance PRINCETON, N.J.— February 29, 2024– Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the fourth quarter of fiscal year 2023. Fourth Quarter Highlights: “We are encouraged by our strong fourth quarter results, driven by improved execution across both software and services,” said William … Continued

https://www.certara.com/pressrelease/certara-reports-fourth-quarter-2023-financial-results/

P21 Live 2024

The 2024 Pinnacle 21 User Group Meeting is your chance to explore, with its architects and your peers, our newly expanded suite of capabilities, from metadata management to accelerated SDTM generation.  Learn best practices from case studies, ask questions about our roadmap, and gather with your fellow data leaders. Location Convene CityView, 30 S 17th St, … Continued

https://www.certara.com/live-events/p21-live-2024/

How to Navigate the FDA Landscape for an Orphan Drug

Rare diseases are a public health priority. FDA has launched several programs and a final guidance to address the unmet need for orphan drugs.

https://www.certara.com/blog/how-to-navigate-the-fda-landscape-for-an-orphan-drug/

Dose Optimization Considerations for Targeted Radiation Therapies

The acquisitions of targeted radiation therapy companies (TRT) Point Biopharma by Eli Lilly and RayzeBio by Bristol Meyer Squibb have sparked investors’ interest in this therapeutic class. A growing number of companies are now developing TRTs, and GlobalData reports that venture capital deals in the field have grown 550% to $408 million in 2023.1 The … Continued

https://www.certara.com/blog/dose-optimization-considerations-for-targeted-radiation-therapies/

CRF design & EDC build in Pinnacle 21

With our CRF design, visualization & study build engine Design CRFs and preview how they’ll look for your EDC – without having to build your study! With a true visualization of your CRFs in Pinnacle 21 (P21), stakeholders can provide changes and approvals, before the EDC is built! That way, once CRFs are approved, you’re … Continued

https://www.certara.com/pinnacle-21-enterprise-software/crf-design-edc-build/

Pinnacle 21 – Clinical Metadata Repository

Define, reuse & govern standards in our Clinical MDR   It all starts with standardization. Get your standards in place, and you’ve paved the way for getting higher quality clinical trial data, faster. Study builds and review cycles take days, not weeks. As a result, patient enrolment can start far earlier. The Pinnacle 21 (P21) … Continued

https://www.certara.com/pinnacle-21-enterprise-software/clinical-metadata-repository/

Thank you for requesting a demo

Thank you for requesting a demo of our Pinnacle 21 Clinical Study Software Suite at Phuse US Connect. You’ll shortly receive an email confirming your request. Next, a member of our team will contact you personally to confirm the meeting point. In the meantime, if you’d like to learn more about how the pharma industry … Continued

https://www.certara.com/thank-you-for-requesting-a-demo-pinnacle-21-conference/

Advancing Services & Software for INDs: How to Expedite IND Filing with a Subscription Model [APAC Webinar]

When choosing how to accomplish your IND submission, there can be many elements to the process that must be determined: budget, software, personnel support, and more.  To further complicate matters, these components must come together in harmony to ensure a smooth filing.  Instead of concentrating individual efforts on research and how to unify the process, … Continued

https://www.certara.com/webinar/advancing-services-software-for-inds-how-to-expedite-ind-filing-with-a-subscription-model-apac-webinar/
7 of 150